Abstract
Symptoms of multiple sclerosis (MS) are highly variable and include impaired senses, instability, and fatigue, making persons with MS (PwMS) ill-suited for the traditional six-month office visit paradigm. Instead, PwMS are well suited for remote monitoring to capture their true impairment. The objective of this work is to investigate the value of free-living data compared to prescribed walking tasks. Wearable sensor data were utilized from six-weeks of data from 25 PwMS. Participants completed a daily 1-minute walk, 30-second standing task, and patient reported outcomes of balance confidence (ABC), fatigue (MFIS) and walking impairment (MSWS). We compared gait and sway, as well as correlated them to patient reported outcomes (PRO). Lastly, we used a regression to determine the variance accounted for (VAF) in each PRO by different data sources. Temporal gait features were moderately correlated (r=0.6 – 0.81) between passive and prescribed walking, however, no postural sway features were correlated with each other. Passive data was found to have greater clinical relevance in our sample of PwMS compared to prescribe tasks for both gait and sway analyses. Passive sway features were found to be moderately related to ABC, MFIS, and MSWS (r=0.42-0.74, VAF=0.42-0.7), while prescribe sway was only correlated to MFIS (r = 0.41, VAF = 0.44). Both passive and prescribed measures of gait were related to ABC and MSWS; stronger relationships were found in the passive data (r = 0.42-0.78, VAF = 0.64-0.78). Additionally, we found the performance increased for passive monitoring with a shorter monitoring duration – highlighting the need to properly match the monitoring and analysis duration to the population. Overall, our findings highlight the importance of including passive free-living analysis in future studies.
Competing Interest Statement
BMM, NA, KMG, SA, and MC are employees of Medidata Solutions. RSM is an inventor on patents and patent applications related to digital health technologies; has advisory relationships with Epicore Biosystems, Pfizer, and Solid Biosciences; is co-founder of PanicMechanic and Biobe; reports research funding from NSF, NIH, Solid Biosciences, Medidata Systems, Kern Family Foundation, MassMutual; has affiliation with Stanford University and the University of Hawaii at Manoa; is associate editor at PLOS Digital Health and npj Digital Medicine.
Funding Statement
This research was funded by the United States National Institutes of Health (NIH) (Grant No. EB027852) and Medidata Solutions.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study protocol received approval from the University of Vermont Institutional Review Board (CHRMS 21-0401).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data is currently unavailable
